TDCCPCS

Targeted delivery of charged membrane impermeant compounds to pain-sensing and cancer cells

Coordinatore	THE HEBREW UNIVERSITY OF JERUSALEM.    more  Organization address address: GIVAT RAM CAMPUS city: JERUSALEM postcode: 91904 contact info Titolo: Ms. Nome: Hani Cognome: Ben-Yehuda Email: send email Telefono: +972 2 6586618
Nazionalità Coordinatore	Israel [IL]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2010-RG
Funding Scheme	MC-IRG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-05-01   -   2015-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE HEBREW UNIVERSITY OF JERUSALEM.  Organization address address: GIVAT RAM CAMPUS city: JERUSALEM postcode: 91904 contact info Titolo: Ms. Nome: Hani Cognome: Ben-Yehuda Email: send email Telefono: +972 2 6586618	IL (JERUSALEM)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Targeted delivery of therapeutic compounds to selective cell types is of great clinical importance and can minimize undesired side effects. Recently, we have introduced a way to target the delivery of sodium channel blockers selectively to nociceptive neurons, and thus capitalize on their effectiveness in blocking action potentials but now only at sites of pain generation. Using this approach we have been able to abolish the response to noxious mechanical and thermal stimuli without motor or tactile deficit (Binshtok et al., Nature). This approach represents a novel concept of targeted delivery and can be used to block activity and also to modulate intracellular signal transduction and metabolism pathways in pain- sensing neurons a well as cancer or any other large cation non-selective channels-expressing cells, while minimizing effects on other types of cells. We now need further explore the utility of this technique for clinical use as an analgesic and also see if the strategy can be used in more generalized way to targeted delivery of charger compounds, beyond charged local anesthetics, to specific types of cells. This project aims to develop methods for targeted delivery of charged local anesthetics to diminish inflammatory, postoperative and neuropathic pain. The second part of this project will be to examine different strategies to expand the approach to selectively target charged cytotoxic or antiproliferative compounds into cancer cells. This interdisciplinary project will incorporate imaging techniques and electrophysiological, histological and behavioral experiments. We believe that the results of our work will lead to a more effective treatment of pain with significantly fewer side effects. Furthermore targeted delivery of chemotherapeutic agents into tumor cell will improve their therapeutic index and hereby limits their side effects as well as the associated pain.'